Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsMarc S. Sabatine, Evan A. Stein, Robert C. Scott et al.|New England Journal of Medicine|2015Cited by 1.5k
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Stanley T. Crooke, Raúl D. Santos et al.|The Lancet|2010Cited by 905
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 studyMarina Cuchel, Daniel J. Rader, Emma A. Meagher et al.|The Lancet|2012Cited by 739
A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaDirk Blom, Evan A. Stein, Tomas Hala et al.|New England Journal of Medicine|2014Cited by 712
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia SyndromeJoseph L. Witztum, Éric Bruckert, Daniel Gaudet et al.|New England Journal of Medicine|2019Cited by 663